Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 542 participants.

Also called NCT04724837

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 542 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04724837
  • EudraCT 2020-004101-32
Other papers using this trial's data
  • Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial Lancet (London, England), 2023-11-25 DOI, PubMed 37931629

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Denmark, Georgia, Hungary, Italy, Japan, Malaysia, Netherlands, Poland, Slovakia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04724837. Randomized; triple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2023-06-01 (actual). Results posted on 2024-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
Acronym
ZENITH-CKD
Intervention (Drug)
Zibotentan
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04724837
Content hash
09f4082dfa0fbdf9cdeffd39860c80f45e9ebad41923fd403a57a57124d4299e